Phospho histone h2ax ser139 clone 20e3

Manufactured by Cell Signaling Technology

Sourced in United States

Phospho-Histone H2AX (Ser139) (clone 20E3) is a rabbit monoclonal antibody that specifically recognizes histone H2AX phosphorylated at serine 139. This antibody can be used to detect DNA double-strand breaks.

Automatically generated - may contain errors

Lab products found in correlation

Cd31 clone mec 13, by BD (1 mentions) Notch1 clone d1e11, by Cell Signaling Technology (1 mentions) 4 6 diamidino 2 phenylindole (dapi), by Thermo Fisher Scientific (1 mentions) Nanog, by R&D Systems (1 mentions) Foxa2, by Santa Cruz Biotechnology (1 mentions) M700101, by Agilent Technologies (1 mentions) M3515, by Agilent Technologies (1 mentions) M7240, by Agilent Technologies (1 mentions) Ab133534, by Abcam (1 mentions) Ab15249, by Abcam (1 mentions)

Spelling variants of this product

Phospho-H2AX (38 citations) Phospho-H2AX (Ser139) (16 citations)

3 protocols using phospho histone h2ax ser139 clone 20e3

Characterization of ADAM10 Antibody Effects

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Authenticated human LIM1215 colon and U251MG glioma cell lines from ATCC were maintained in RPMI 1640/10% FCS, while HEK293 cells were maintained in DMEM 10% FCS. ADAM10 monoclonal antibodies 8C7 and 4A11 have been previously described [19 (link),20 (link)]. Commercially available antibodies were obtained: Phospho-Histone H2AX (Ser139) (clone 20E3) and Notch1 (clone D1E11) from Cell Signalling Technologies, Danvers, MA, USA), CD31 (clone MEC13.3, BD Pharmingen, San Diego, CA, USA) and pan-actin (ACTN05 (C4), Thermofisher, Waltham, MA, USA).

Yan H., Vail M.E., Hii L., Guo N., McMurrick P.J., Oliva K., Wilkins S., Saha N., Nikolov D.B., Lee F.T., Scott A.M, & Janes P.W. (2022). Preferential Antibody and Drug Conjugate Targeting of the ADAM10 Metalloprotease in Tumours. Cancers, 14(13), 3171.

+ Open protocol

+ Expand

Immunostaining of Stem Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cells were fixed by incubation in 4% paraformaldehyde for 15 minutes and incubated in blocking buffer (0.3% Triton-X100 in PBS) for 30 minutes. Cells were stained with primary antibodies in PBS supplemented with 1% BSA at 4°C overnight, washed and stained with secondary antibodies in PBS supplemented with 0.1% BSA for 1 hour at room temperature, in the dark. Nuclei were stained by DAPI (Invitrogen). The following primary antibodies were used: TH (1:1000; Pel Freeze), FOXA2 (Santa Cruz; 1:200), OCT4 (1:100; Santa Cruz), NANOG (1:50; R&D), and phospho-Histone H2A.X (Ser139; clone 20E3; 1:400; Cell Signaling).

Vera E., Bosco N, & Studer L. (2016). GENERATING LATE-ONSET HUMAN iPSC-BASED DISEASE MODELS BY INDUCING NEURONAL AGE-RELATED PHENOTYPES THROUGH TELOMERASE MANIPULATION. Cell reports, 17(4), 1184-1192.

+ Open protocol

+ Expand

Immunohistochemical and DNA Repair Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

Rucaparib was kindly provided by Clovis Oncology. The following antibodies were used for WEHI PDX immunohistochemistry: p53 (M700101 1:100; Dako), Ki67 (M7240 1:50; Dako), Cytokeratin (Pan-CK; M3515 1:200; Dako), PAX8 (10336-1-AP 1:20000; Proteintech), and WT1 (ab15249; 1:800; Abcam). For DNA repair foci experiments, rabbit anti-human RAD51 (ab133534, Abcam) and rabbit anti-human γH2AX antibody (Phospho-Histone H2A.X Ser139; clone 20E3, #9718, Cell Signaling Technologies) were used. For BRCA1 immunoblotting, the mouse monoclonal antibody MS110 antibody was used (Calbiochem OP92).

Nesic K., Krais J.J., Vandenberg C.J., Wang Y., Patel P., Cai K.Q., Kwan T., Lieschke E., Ho G.Y., Barker H.E., Bedo J., Casadei S., Farrell A., Radke M., Shield-Artin K., Penington J.S., Geissler F., Kyran E., Zhang F., Dobrovic A., Olesen I., Kristeleit R., Oza A., Ratnayake G., Traficante N., DeFazio A., Bowtell D.D., Harding T.C., Lin K., Swisher E.M., Kondrashova O., Scott C.L., Johnson N, & Wakefield M.J. (2023). BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance. medRxiv.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!